In another article from RTTNews, Abbott Labs is working on getting Humira approved for Ulcerative Colitis, or UC for short. The % of people that went into remission isn't very impressive. It's significant, but barely.
According to the company, of the 248 patients treated with HUMIRA in the study, 16.5 percent achieved clinical remission compared to 9.3 percent on placebo at week 8. At week 52, 17.3 percent achieved clinical remission compared to 8.5 percent on placebo. These results were statistically significant compared to placebo.
HUMIRA is not approved for the treatment of UC. Abbott recently submitted applications to both the U.S. Food and Drug Administration and the European Medicines Agency seeking approval to market HUMIRA for the treatment of moderate to severe UC.